• Karin L Heckman, William DeCoteau, Ana Estevez, Kenneth J Reed, Wendi Costanzo, David Sanford, James C Leiter, Jennifer Clauss, Kylie Knapp, Carlos Gomez, Patrick Mullen, Elle Rathbun, Kelly Prime, Jessica Marini, Jamie Patchefsky, Arthur S Patchefsky, Richard K Hailstone, and Joseph S Erlichman.
• Departments of Biology and ‡Psychology, St. Lawrence University , Canton, New York 13617, United States.
• ACS Nano. 2013 Dec 23; 7 (12): 10582-96.

AbstractCerium oxide nanoparticles are potent antioxidants, based on their ability to either donate or receive electrons as they alternate between the +3 and +4 valence states. The dual oxidation state of ceria has made it an ideal catalyst in industrial applications, and more recently, nanoceria's efficacy in neutralizing biologically generated free radicals has been explored in biological applications. Here, we report the in vivo characteristics of custom-synthesized cerium oxide nanoparticles (CeNPs) in an animal model of immunological and free-radical mediated oxidative injury leading to neurodegenerative disease. The CeNPs are 2.9 nm in diameter, monodispersed and have a -23.5 mV zeta potential when stabilized with citrate/EDTA. This stabilizer coating resists being 'washed' off in physiological salt solutions, and the CeNPs remain monodispersed for long durations in high ionic strength saline. The plasma half-life of the CeNPs is ∼4.0 h, far longer than previously described, stabilized ceria nanoparticles. When administered intravenously to mice, the CeNPs were well tolerated and taken up by the liver and spleen much less than previous nanoceria formulations. The CeNPs were also able to penetrate the brain, reduce reactive oxygen species levels, and alleviate clinical symptoms and motor deficits in mice with a murine model of multiple sclerosis. Thus, CeNPs may be useful in mitigating tissue damage arising from free radical accumulation in biological systems.

40 keywords...

hide…